Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

Mark D. Hauge, Harry J. Long, Lynn C. Hartmann, John H. Edmonson, Maurice J. Webb, John Su

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

A Phase II trial of an intravenous preparation of Hexamethylmelamine was performed in ovarian cancer. Patients who had received prior Platinum based chemotherapy and had measurable disease were eligible. Among 15 evaluable patients, there were no objective responses. Two patients did show clinical and laboratory evidence of improvement. Toxicity was predominantly nausea and vomiting with minimal other toxicity. This intravenous form of Hexamethylmelamine has not shown meaningful activity in ovarian cancer patients who have failed prior platinum treatment.

Original languageEnglish (US)
Pages (from-to)299-301
Number of pages3
JournalInvestigational New Drugs
Volume10
Issue number4
DOIs
StatePublished - Nov 1 1992

    Fingerprint

Keywords

  • chemotherapy
  • hexamethylmelamine ovarian cancer
  • ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Hauge, M. D., Long, H. J., Hartmann, L. C., Edmonson, J. H., Webb, M. J., & Su, J. (1992). Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Investigational New Drugs, 10(4), 299-301. https://doi.org/10.1007/BF00944184